BackBiocryst Pharmaceuticals Overview

Biocryst Pharmaceuticals Inventory

Track Biocryst Pharmaceuticals's inventory ($6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$5.99M

Peer average

Loading

Biocryst Pharmaceuticals Inventory History

Loading

Biocryst Pharmaceuticals vs. peers: Inventory Comparison

Loading

Biocryst Pharmaceuticals Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Biocryst Pharmaceuticals (BCRX) FAQ

Biocryst Pharmaceuticals's inventory stands at $6M as of March 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Biocryst Pharmaceuticals reported $6M in inventory versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Biocryst Pharmaceuticals's inventory evolved across reporting periods, while the comparison chart places BCRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Biocryst Pharmaceuticals's reading of $6M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.